The relative effects of different systemic immunosuppressives on skin cancer development in organ transplant patients

Dermatologic Therapy

Volumn 18, Issue 1, 2005, Pages 1-11

  Durando, Bianca ^a   Reichel, Jennifer ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Immunosuppressive therapy; Skin cancer; Transplantation

Indexed keywords

ALEMTUZUMAB; ANTIMETABOLITE; AZASAN; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANESTHESIA INDUCTION; CARCINOGENESIS; GRAFT REJECTION; HUMAN; INCIDENCE; MAINTENANCE THERAPY; ORGAN TRANSPLANTATION; PATIENT EDUCATION; REVIEW; SKIN CANCER;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; SKIN NEOPLASMS;

EID: 18844371465     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2005.05007.x     Document Type: Review

References (64)

1. United Network of Organ Sharing Database Website, 2003. Available at: www.optn.org/data/annualReport.asp. Last accessed March 2, 2005.
2. Edwards NM et al. Cardiac transplantation in over 1000 patients: a single institution experience from Columbia University. Clin Transpl 1999: 249-261.
3. Hariharan S et al. Improved graft survival after renal transplantation in the United States, 1988-1996. N Engl J Med 2000: 342 (9): 605-612.
4. Sheil AG. Development of malignancy following renal transplantation in Australia and New Zealand. Transplant Proc 1992: 24 (4): 1275-1279.
5. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf 2000: 23 (2): 101-113.
6. Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther 2000: 7 (2): 147-156.
7. Penn I. Cancers in cyclosporine-treated versus azathioprine-treated patients. Transplant Proc 1996: 28 (2): 876-878.
8. Sheil AG et al. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993: 25 (1 Part 2): 1383-1384.
9. Hartevelt MM et al. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990: 49 (3): 506-509.
10. Jensen P et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999: 40 (2 Part 1): 177-186.
11. Ong CS et al. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol 1999: 40 (1): 27-34.
12. Fortina AB et al. Skin cancer in heart transplant recipients: frequency and risk factor analysis. J Heart Lung Transplant 2000: 19 (3): 249-255.
13. Euvrard S et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995: 33 (2 Part 1): 222-229.
14. Veness MJ et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer 1999: 85 (8): 1758-1764.
15. Frezza EE, Fung JJ, van Thiel DH. Nonlymphoid cancer after liver transplantation. Hepatogastroenterology 1997: 44 (16): 1172-1181.
16. Helderman JH, Bennett WM, Cibrik DM, Kaufam DB, Klein A, Takemoto SK. 2002 Annual Report of the U.S. Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network: Transplant Data Chapter IV Immunosuppression: Practice and Trends 2002. Rockville, MD and Richmond, VA: HHS/HRSA/OSP/DOT and UNOS, 2002.
17. Kaufman DB, Shapiro R, Lucey MR, Cherikh WS, Bustami R, Dyke DB. 2003 Annual Report of the U.S. Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network: Transplant Data Chapter IV Immunosuppression: Practice and Trends 1992-2001. Rockville, MD and Richmond, VA: HHS/OSP/DOT and UNOS, 2003.
18. Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 2000: 47 (2-3): 63-83.
19. Ochiai T, Nakajima K, Nagata M, et al. Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc 1987: 19 (1 Part 2): 1284-1286.
20. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998: 31 (5): 335-340.
21. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996: 14: 483-510.
22. Kim HS, Raskova J, Degiannis K, Raska K, Jr. Effects of cyclosporine and rapamycin on immunoglobulin production by preactivated human B cells. Clin Exp Immunol 1994: 96 (3): 508-512.
23. Ducloux D, Carron PL, Rebibou JM et al. CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients. Transplantation 1998: 65 (9): 1270-1272.
24. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003: 348 (17): 1681-1691.
25. Stockfleth E, Ulrich C, Meyer T, Christophers E. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res 2002: 160: 251-258.
26. Blohme I, Larko O. Skin lesions in renal transplant patients after 10-23 years of immunosuppressive therapy. Acta Derm Venereol 1990: 70 (6): 491-494.
27. Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 1996: 61 (5): 715-721.
28. Ramsay HM, Fryer AA, Reece S, Smith AG, Harden PN. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000: 36 (1): 167-176.
29. Blohme I, Larko O. No difference in skin cancer incidence with or without cyclosporine - a 5-year perspective. Transplant Proc 1992: 24 (1): 313.
30. Bunney MH, Benton EC, Barr BB, Smith IW, Anderton JL, Hunter JA. The prevalence of skin disorders in renal allograft recipients receiving cyclosporin A compared with those receiving azathioprine. Nephrol Dial Transplant 1990: 5 (5): 379-382.
31. Glover MT, Deeks JJ, Raftery MJ, Cunningham J, Leigh IM. Immunosuppression and risk of nonmelanoma skin cancer in renal transplant recipients. Lancet 1997: 349 (9049): 398.
32. Hiesse C, Larue JR, Kriaa F, et al. Incidence and type of malignancies occurring after renal transplantation in conventionally and in cyclosporine-treated recipients: single-center analysis of a 20-year period in 1600 patients. Transplant Proc 1995: 27 (4): 2450-2451.
33. Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Fauchald P. Are renal transplant recipients on CsA-based immunosuppressive regimens more likely to develop skin cancer than those on azathioprine and prednisolone? Transplant Proc 1999: 31 (1-2): 1120.
34. Jonas S, Rayes N, Neumann U, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997: 80 (6): 1141-1150.
35. Kasiske BL, Zinder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004: 4 (6): 905-913.
36. Robson RA, Opelz G, Cecka JM. Risk of PTLD and other malignancies in renal transplant patients treated with MMF: a prospective observational cohort study [abstract]. Am J Transplant 2003: 3 (Suppl. 5): 187.
37. Mathew TH, Kreis H, Doyen K. Malignancy in renal transplant recipients receiving sirolimus maintenance therapy 2-year follow-up from five multicenter studies [abstract]. Transplantation 2002: 74 (Suppl.): 131.
38. Yakupoglu Y, Kahan B. Low incidence of malignancy among renal transplant recipients treated with a sirolimus-CsA regimen [abstract]. Am J Transplant 2003: 3 (Suppl. 5): 186.
39. Euvrard S, Ulrich C, Lefrancois N. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg 2004: 30 (4 Part 2): 628-633.
40. Kelly GE, Meikle W, Sheil AG. Effects of immunosuppressive therapy on the induction of skin tumors by ultraviolet irradiation in hairless mice. Transplantation 1987: 44 (3): 429-434.
41. Hrelia P, Murelli L, Scotti M, Paolini M, Cantelli-Forti G. Organospecific activation of azathioprine in mice: role of liver metabolism in mutation induction. Carcinogenesis 1988: 9 (6): 1011-1015.
42. Elion GB. The purine path to chemotherapy. Science 1989: 244 (4900): 41-47.
43. Hemmens VJ, Moore DE. Photochemical sensitization by azathioprine and its metabolites - II. Azathioprine and nitroimidazole metabolites. Photochem Photobiol 1986: 43 (3): 257-262.
44. Lennard L, Thomas S, Harrington CI, Maddocks JL. Skin cancer in renal transplant recipients is associated with increased concentrations of 6-thioguanine nucleotide in red blood cells. Br J Dermatol 1985: 113 (6): 723-729.
45. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999: 397 (6719): 530-534.
46. Beatty PR, Krams SM, Esquivel CO, Martinez OM. Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. Transplantation 1998: 65 (9): 1248-1255.
47. Baksh S, DeCaprio JA, Burakoff SJ. Calcineurin regulation of the mammalian G0/G1 checkpoint element, cyclin-dependent kinase 4. Oncogene 2000: 19 (24): 2820-2827.
48. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003: 76 (3): 597-602.
49. Schumacher G, Oidtmann M, Rosewicz S, et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc 2002: 34 (5): 1392-1393.
50. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by anti-angiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002: 8 (2): 128-135.
51. Muthukkumar S, Ramesh TM, Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 1995: 60 (3): 264-270.
52. Kasiske BL, Vazquez MA, Harmon WE, et al. Rapamycin inhibits the interleukin-10 signal transduction pathway and the growth of Epstein-Barr virus B cell lymphomas. Cancer Res 2003: 63 (15): 4472-4480.
53. Kasiske BL et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000: 11 (Suppl. 15): S1-S86.
54. Stasko T, Brown MD, Carucci JA, et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg 2004: 30 (4 Part 2): 642-650.
55. Christenson LJ, Geusau A, Ferrandiz C, et al. Specialty clinics for the dermatologic care of solid-organ transplant recipients. Dermatol Surg 2004: 30 (4 Part 2): 598-603.
56. Robinson JK, Rigel DS. Sun protection attitudes and behaviors of solid-organ transplant recipients. Dermatol Surg 2004: 30 (4 Part 2): 610-615.
57. Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Aggressive squamous cell carcinomas in organ transplant recipients. Transplant Proc 1995: 27 (2): 1767-1768.
58. Ramos HC, Reyes J, Abu-Elmagd K, et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 1995: 59 (2): 212-217.
59. Moloney FJ, Kelly PO, Kay EW, Conlon P, Murphy GM. Maintenance versus reduction of immunosuppression in renal transplant recipients with aggressive squamous cell carcinoma. Dermatol Surg 2004: 30 (4 Part 2): 674-678.
60. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002, 47 (1): 1-17.
61. Starzl TE, Demetris AJ, Trucco M, et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 1993: 17 (6): 1127-1152.
62. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration: chimerism, and graft acceptance. Lancet 1992: 339 (8809): 1579-1582.
63. Otley CC, Coldiron BM, Stasko T, Goldman GD. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol 2001: 137 (4): 459-463.
64. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998: 351 (9103): 623-628.